Rezolute
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Rezolute sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Rezolute: 4 sponsored US clinical trials, 1 recruiting.
Rezolute sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 2 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tumor Hyperinsulinism (Tumor HI), with 1 trials.
Upper-quartile sponsor footprint
Rezolute sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
NCT06881992
RZ358 Treatment for Congenital Hyperinsulinism
NCT06208215
Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)
NCT05712720
An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
NCT04538989
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Rezolute pipeline
1 recruiting of 4 indexed (25% open); 2 completed (50%).
Phase mix: 2 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Tumor Hyperinsulinism (Tumor HI) (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rezolute: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Rezolute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Rezolute page
4 registered trials is a research-attention snapshot, not an endorsement of Rezolute or any single study.
- 1 of Rezolute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Tumor Hyperinsulinism (Tumor HI) is the condition Rezolute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tumor Hyperinsulinism (Tumor HI) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Rezolute pipeline card: 4 registered trials from official public datasets.Report a data error.